Minretumomab
Minretumomab
Minretumomab (pronunciation: min-re-tu-mo-mab) is a monoclonal antibody designed for the treatment of certain types of cancer. It is a type of immunotherapy that uses the body's immune system to help fight cancer.
Etymology
The name "Minretumomab" is derived from the International Nonproprietary Names (INN), where "mab" stands for monoclonal antibody, "tu" for tumor, "re" for rat (indicating the murine origin of the antibody), and "min" is a prefix used in the naming of monoclonal antibodies.
Usage
Minretumomab is used in the treatment of certain types of cancer, including ovarian cancer and mesothelioma. It works by binding to specific proteins found on the surface of cancer cells, which helps the immune system to recognize and destroy these cells.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Immunotherapy: A type of therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer, infection, and other diseases.
- Ovarian cancer: A type of cancer that begins in the ovaries.
- Mesothelioma: A type of cancer that occurs in the thin layer of tissue that covers the majority of your internal organs (mesothelium).
See Also
External links
- Medical encyclopedia article on Minretumomab
- Wikipedia's article - Minretumomab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski